CALU

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab

Animals1

Effects

Vimentin aggregates

downin mice1

1 study

CALU decreases vimentin aggregates in mice.
“calumenin collaborates with the TRiC complex to facilitate proper vimentin folding and recruits the chaperonin subunit Chaperonin Containing TCP1 Subunit 2 (CCT2) to degrade misfolded vimentin aggregates.”
Animalslung
Calumenin prevents fibroblast senescence and lung aging by promoting vimentin proteostasis
Proceedings of the National Academy of Sciences of the United States of America20 Jan 2026

Latest

1 in 12 months

PNAS20 Jan

Calumenin prevents fibroblast senescence and lung aging by promoting vimentin proteostasis

Experiments in miceLung

Paper

CALU

Effects

Latest

Calumenin prevents fibroblast senescence and lung aging by promoting vimentin proteostasis

Related